Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies
Manuela Di Fusco, Jay Lin, Shailja Vaghela, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 4, pp. 435-451
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 86
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 43
Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2251833-e2251833
Open Access | Times Cited: 25
Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19
Amie Scott, Wajeeha Ansari, Farid Khan, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 15
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 10
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
Jessica Widdifield, Jeffrey C. Kwong, Simon Chen, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e430-e440
Open Access | Times Cited: 38
AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study
Wilhelmine Meeraus, Mark Joy, Mario Ouwens, et al.
Journal of Infection (2024) Vol. 88, Iss. 4, pp. 106129-106129
Open Access | Times Cited: 7
Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France
Laura Semenzato, Jérémie Botton, Jérôme Drouin, et al.
The Lancet Regional Health - Europe (2022) Vol. 19, pp. 100441-100441
Open Access | Times Cited: 27
Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia
Daphne Day, Lisa Grech, Mike Nguyen, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 851-851
Open Access | Times Cited: 25
COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
Yousra Kherabi, Odile Launay, Liêm Binh Luong Nguyen
Viruses (2022) Vol. 14, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 20
One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort
Paul Loubet, Linda Wittkop, Läétitia Ninove, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 388.e1-388.e8
Open Access | Times Cited: 18
Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort
Erika Zecca, Manuela Rizzi, Stelvio Tonello, et al.
Viruses (2022) Vol. 14, Iss. 8, pp. 1766-1766
Open Access | Times Cited: 17
Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19
Aroona Razzaq, Cyrollah Disoma, Yuzheng Zhou, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 11
Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions—United States, 2020–2022
Anna Bratcher, Jefferson M. Jones, William A. Meyer, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313620-e0313620
Open Access
Assessing the Vulnerability of Splenectomized Patients to Severe COVID-19 Outcomes: A Systematic Review and Meta-Analysis
Francesco Paolo Bianchi, Massimo Giotta, Andrea Martinelli, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 203-203
Open Access
Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study
Christina Qian, Karissa Johnston, María Tinajero, et al.
Journal of Medical Economics (2025), pp. 1-21
Open Access
The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis
Lin Yuan, Madison Stoddard, Sharanya Sarkar, et al.
Vaccines (2025) Vol. 13, Iss. 4, pp. 368-368
Open Access
Analysis of humoral and cellular responses after vaccination against SARS-CoV-2 in patients with immune-mediated diseases
Thomas Escoda, Sylvie Jordana, L. Chiche, et al.
Diagnostic Microbiology and Infectious Disease (2025) Vol. 112, Iss. 3, pp. 116825-116825
Closed Access
Burden of COVID-19 in immunocompromised patients in Germany: a retrospective, observational Study on Health Insurance Data from 2021 to 2022
Julia Weinmann‐Menke, Clemens‐Martin Wendtner, Dennis Häckl, et al.
Infection (2025)
Open Access
Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression
Marek Petráš, Roman Máčalík, D Janovská, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design
Adeleke Fowokan, Hasina Samji, Joseph H. Puyat, et al.
International Journal of Infectious Diseases (2022) Vol. 127, pp. 162-170
Open Access | Times Cited: 15
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Hung Van Nguyen, Hoang Linh Nguyen, Pham Dang Lan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 18, pp. 6497-6553
Closed Access | Times Cited: 9
Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons
Karim Yaqub Ibrahim, R. Moreira, C. Santos, et al.
Revista do Instituto de Medicina Tropical de São Paulo (2024)
Open Access | Times Cited: 3
Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England
Daniel Tzu-Hsuan Chen, Emma Copland, Jennifer Hirst, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study
Heather Whitaker, Ruby S. M. Tsang, Rachel Byford, et al.
Journal of Infection (2023) Vol. 87, Iss. 4, pp. 315-327
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top